Physician profile
Robert Walter
NPI 1023123973
$1,789.24
in general payments reported to CMS, 2019-2025
24 companies · $437 in 2025
The $437 reported for 2025 was more than what 92% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $40.86 · 2021: $124 · 2022: $267 · 2023: $265 · 2024: $303 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,005.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $369.28 | 2019-2024 | Jornay Pm |
| Kaleo, INC. | $179.29 | 2019-2024 | Auvi-Q |
| Merck Sharp & Dohme LLC | $160.94 | 2021-2025 | Vaxneuvance, Vaxelis, Rotateq |
| Collegium Pharmaceutical, INC. | $143.02 | 2025 | Jornay Pm |
| Sanofi Pasteur INC. | $136.72 | 2019-2025 | |
| Pfizer INC. | $93.93 | 2021-2024 | |
| Seqirus USA INC | $79.41 | 2022-2025 | Flucelvax, Flucelvax Quadrivalent |
| Tris Pharma INC | $74.79 | 2019-2022 | |
| Alk-Abello, INC | $73.69 | 2023-2025 | Ragwitek, Odactra, Grastek |
| Corium, LLC | $67.64 | 2022-2025 | Azstarys |
| Sanofi-Aventis U.S. LLC | $66.34 | 2025 | |
| Sobi, INC | $65.36 | 2019-2023 | |
| Adlon Therapeutics L.P. | $58.05 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $45.52 | 2024 | Relexxii |
| Takeda Pharmaceuticals U.S.A., INC. | $27.58 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi US Services INC. | $20.17 | 2024 | |
| Alexion Pharmaceuticals, INC. | $19.80 | 2019 | |
| Biomarin Pharmaceutical INC. | $17.74 | 2024 | Voxzogo 1.2mg |
| Astrazeneca Pharmaceuticals Lp | $17.00 | 2024 | |
| Glaxosmithkline, LLC. | $16.25 | 2024 | Bexsero |
| Aytu Biopharma, INC. | $15.67 | 2025 | |
| Mission Pharmacal Company | $14.22 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $14.10 | 2025 | Neffy |
| Arbor Pharmaceuticals, INC. | $12.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Walter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.